Regeneron stock recovered and closed higher Monday after the drugmaker preannounced light sales of a high-dose version of its blockbuster eye drug, Eylea. Please watch the video at Investors.com ...

Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have been boosted by FDA approval of a new high-dose formulation of the drug. The US regulator ...

Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

Two one-shot doses of 4D-150 are being tested in the study and compared to Eylea. The high dose of the gene therapy – which is designed to express both aflibercept and an RNA interference (RNAi ...

Brokerage slashed price target to $738 from $1130. The brokerage highlighted limited adoption of high-dose Eylea amid rising branded and biosimilar competition. UBS projects a 14% drop in Eylea ...

Regular dose Eylea sales in the US were $1.2 billion, or an 11% year-on-year decline, while Eylea high-dose sales in the US were $305 million, or 148% year-on-year growth. Although Roche’s ...

Despite lower-than-expected sales for Eylea High Dose, the drug used to treat eye diseases, sales of Eylea 2mg exceeded expectations. Jefferies also maintained a Buy rating, albeit with a revised ...

The Eylea franchise -- including a high-dose (HD) formulation that first earned approval in 2023 -- is facing stiff competition, biosimilar and otherwise. The medicine's sales growth has slowed ...

Goldman Sachs (NYSE:GS) reiterated a Buy rating, highlighting late-stage pipeline opportunities. Despite lower-than-expected sales for Eylea High Dose, the drug used to treat eye diseases, sales of ...